Filing Details

Accession Number:
0001209191-21-017020
Form Type:
4
Zero Holdings:
No
Publication Time:
2021-03-03 17:10:54
Reporting Period:
2021-03-01
Accepted Time:
2021-03-03 17:10:54
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1623526 Stoke Therapeutics Inc. STOK () DE
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1181556 A Arthur Levin C/O Stoke Therapeutics, Inc.
45 Wiggins Avenue
Bedford MA 01730
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-03-01 2,776 $0.40 2,776 No 4 M Direct
Common Stock Acquisiton 2021-03-01 1,842 $0.40 4,618 No 4 M Direct
Common Stock Acquisiton 2021-03-01 7,882 $0.60 12,500 No 4 M Direct
Common Stock Disposition 2021-03-01 7,543 $60.55 4,957 No 4 S Direct
Common Stock Disposition 2021-03-01 4,957 $61.14 0 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 M Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Director Stock Option (Right to Buy) Disposition 2021-03-01 2,776 $0.00 2,776 $0.40
Common Stock Director Stock Option (Right to Buy) Disposition 2021-03-01 1,842 $0.00 1,842 $0.40
Common Stock Director Stock Option (Right to Buy) Disposition 2021-03-01 7,882 $0.00 7,882 $0.60
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
0 2026-02-11 No 4 M Direct
0 2027-02-02 No 4 M Direct
8,764 2028-04-02 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 17,979 Indirect Arthur A. Levin, Ph.D., Trustee, Butler-Levin Revocable Trust
Footnotes
  1. The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.
  2. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.89 to $60.88 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  3. The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.90 to $61.80 per share, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
  4. The option is 100% vested and exercisable.
  5. The option vested as to 1/48th of the total shares on February 28, 2018, and then 1/48th of the total shares vest at the end of each month thereafter, subject to the reporting person's continued service to the issuer through each vesting date.